Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.

Addy, Carol; Li, Susie; Agrawal, Nancy; Stone, Julie; Majumdar, Anup; Zhong, Ling; Li, Hankun; Yuan, Jinyu; Maes, Andrea; Rothenberg, Paul; Cote, Josee; Rosko, Kim; Cummings, Corinne; Warrington, Steven; Boyce, Malcolm; Gottesdiener, Keith; Stoch, Aubrey; Wagner, John

Addy, Carol; Li, Susie; Agrawal, Nancy; Stone, Julie; Majumdar, Anup; Zhong, Ling; Li, Hankun; Yuan, Jinyu; Maes, Andrea; Rothenberg, Paul; Cote, Josee; Rosko, Kim; Cummings, Corinne; Warrington, Steven; Boyce, Malcolm; Gottesdiener, Keith; Stoch, Aubrey; Wagner, John.

Affiliation

Addy C; Clinical Pharmacology, Merck Research Laboratories, 33 Avenue Louis Pasteur, HB3-429, Boston, MA 02115, USA. carol_addy@merck.com

J Clin Pharmacol ; 48(4): 418-27, 2008 Apr.

Article in En | MEDLINE | ID: mdl-18258750

Subject(s)

Amides/adverse effects; Amides/pharmacokinetics; Anti-Obesity Agents/adverse effects; Anti-Obesity Agents/pharmacokinetics; Pyridines/adverse effects; Pyridines/pharmacokinetics; Receptor, Cannabinoid, CB1/agonists; Adolescent; Adult; Amides/pharmacology; Analysis of Variance; Anti-Obesity Agents/pharmacology; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Male; Pyridines/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Anti-Obesity Agents / Receptor, Cannabinoid, CB1 / Amides Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: J Clin Pharmacol Year: 2008 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google